BioSpace News Archive

Business

Scaling New Science with Big Impact is Karius CMO Brad Perkins’ Driving Force

Brad Perkins, M.D., newly appointed CMO of Karius, has had his eyes on grand scientific achievements since childhood.

June 23, 2021
·
5 min read
·
Gail Dutton
Policy

Customs Officers Seize Illicit Remdesivir Treatments Bound for Mexico

Crisis has a way of opening doors of opportunity for fraud around the globe. The COVID-19 pandemic has brought not only a fresh slew of financial schemes, but pharmaceutical fraud as well.

June 23, 2021
·
3 min read
·
Kate Goodwin
Business

Third Rock-Seeded Abata Aims Tregs, $95 Million at Autoimmune Diseases

The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.

June 23, 2021
·
3 min read
·
Alex Keown
Business

Money on the Move: June 16 – 22

Life sciences advances continue to be an exciting opportunity for investors. Here’s a glance at the companies attracting fresh funding the past week.

June 23, 2021
·
5 min read
·
Kate Goodwin
Policy

China Approves Its First Commercial CAR T-Cell Therapy

The medical regulator’s green light is a milestone in the global fight against specific types of late-stage blood cancer, as CAR T-cell therapy has been found to be effective against them.

June 23, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

With Spotlight on Alzheimer’s Disease and Biogen, Competitors’ Stocks Soar

It’s been a bumpy ride for Biogen as news swirls around its overall Alzheimer’s program… but not for its competitors with investigational therapies for that disease.

June 23, 2021
·
4 min read
·
Gail Dutton
Business

Four New Biotechs Launch to Combat MD, NASH, Parkinson’s and More

There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.

June 23, 2021
·
3 min read
·
Mark Terry
Drug Development

Is an mRNA Flu Vaccine on the Horizon?

The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.

June 23, 2021
·
2 min read
·
Brandon May
Business

Under Fire From Investors, Walmsley Outlines Vision for GSK

CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.

June 23, 2021
·
3 min read
·
Alex Keown
Business

Dutch Biotech Acquires Corlieve to Develop Treatment for Temporal Lobe Epilepsy

uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.

June 23, 2021
·
2 min read
·
Vanessa Doctor, RN